Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31570487 | 0.94 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL21585195 | 0.82 | P2RX7 (0.40) | P2RX7MAPK1 | |
| SCHEMBL31570452 | 0.81 | P2RX7 (0.55) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL25136361 | 0.80 | MAPK1 (0.46) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL30708588 | 0.78 | P2RX7 (0.43) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL30965862 | 0.75 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL31570509 | 0.73 | P2RX7 (0.42) | P2RX7MAPK1 | |
| SCHEMBL19326734 | 0.72 | P2RX7 (0.38) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL31387272 | 0.72 | P2RX7 (0.44) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL3655929 | 0.71 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025026955-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2025-02-06 | — | — | WO | disclosed |
| EP-3897832-B1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2022-02-03 | — | — | US | disclosed |
| EP-3897832-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020128768-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| WO-2016154075-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | P2RX7 1427/4885MAPK1 104/4885LPL 1942/4885 |
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | CFTR, PKD2, PKD1 | P2RX7 29/4885MAPK1 4000/4885LPL 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.